- Immunotherapy developer for the treatment of cancer Scancell Holdings said it had been granted a US patent for the first clinical candidate from an immunotherapy platform.

US patent number 10,233,220, entitled Anti-tumour Response to Modified Self-epitopes was granted on 19 March.

It claimed methods of stimulating an immune response to a tumour and methods of treating cancer using peptides of Modi-1.

Additional claims that aim to protect other aspects of the company's Moditope platform were being pursued in the US.

Grant in the US followed grant of corresponding patents in Europe, as announced last year, South Africa and Australia, and acceptance for grant in China.

Story provided by